Does Ascorbic Acid Reduce Sympathoexcitation in CHF?

Radboud University Medical Center

Status: Completed

Conditions: Heart Failure

Treatments: Drug: vitamin C; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00550121

CHFVIT

Details and patient eligibility

About

In CHF central sympathetic activity is increased. ROS formation seems to play a role in this process. This study analyzes the effect of vitamin C as an antioxidant on central sympathetic activity in CHF

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Heart failure of at least New York Heart Association (NYHA) class II
• Left ventricular ejection fraction (LVEF) <= 40%
• Age 20-80 years

Exclusion criteria

• Necessity of short-term PCI, CABG or heart transplantation,
• Chronic disease of the autonomic nervous system,
• diabetes mellitus,
• use of tricyclic antidepressant drugs and/or a-adrenergic receptor antagonists.

Trial design

0 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: vitamin C

2

Placebo Comparator group

Treatment:

Drug: placebo